CORDIS
EU research results

CORDIS

English EN

Mechanisms and Treatment of Migraine and its Chronification

Objective

Migraine is a common brain disorder, typically characterised by recurring, incapacitating attacks of 1-3 days of severe headache, autonomic dysfunction, and sometimes aura symptoms. The disease affects 15% of all European citizens including children, ranks among the WHO top 12 of most disabling and undertreated disorders, and is responsible for the highest socio-economic burden of any brain ailment in Europe.

Migraine attacks typically strike bi-monthly, and in 25% of patients once a week or more. Many patients may progress to “chronic migraine” with near-daily headaches and high disability (chronification). There is desperate need of effective prophylactic treatments to prevent attacks and chronification. Current medications are only moderately effective and often poorly tolerated, mainly due to lack of understanding of how attacks are triggered and why their frequency may increase so dramatically. Overuse of painkillers and triptans, are recognised risk factors for chronification, as are comorbid depression, stress, and obesity. Central sensitisation of pain signalling pathways appears to be pivotal to the chronification proces.

EUROHEADPAIN will use established and evolving human and translational animal models to: (a) identify pathways and biomarkers for the triggering and chronification of migraine attacks; (b) decipher the modulatory effects of (hypothalamic) brain circuitries on trigeminal processing, sensitisation, and chronification; (c) assess the effects and mode of action of migraine-provoking molecules; and (d) evaluate the efficacy and mode of action of neuromodulation (in collaboration with an SME) and second messenger-blocking drugs in the treatment of chronic migraine. We expect important spin-offs to the understanding of other chronic pain disorders. The pharmaceutical industry will be engaged once treatable targets have been identified to develop novel treatments to reduce the disability and socio-economic burden due to migraine.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

ACADEMISCH ZIEKENHUIS LEIDEN

Address

Albinusdreef 2
2333 Za Leiden

Netherlands

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 1 511 738

Administrative Contact

Linda Ouwerkerk (Mrs.)

Participants (13)

Sort alphabetically

Sort by EU Contribution

Expand all

UNIVERSITE DE LIEGE

Belgium

EU Contribution

€ 592 544

UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF

Germany

EU Contribution

€ 468 440

GENOME RESEARCH LIMITED

United Kingdom

HELSINGIN YLIOPISTO

Finland

EU Contribution

€ 1 039 364

QUEENSLAND INSTITUTE OF MEDICAL RESEARCH

Australia

SCUOLA INTERNAZIONALE SUPERIORE DI STUDI AVANZATI DI TRIESTE

Italy

EU Contribution

€ 333 680

FRIEDRICH-ALEXANDER-UNIVERSITAET ERLANGEN NUERNBERG

Germany

EU Contribution

€ 552 680

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

United States

REGION HOVEDSTADEN

Denmark

EU Contribution

€ 711 320

CEFALY TECHNOLOGY

Belgium

EU Contribution

€ 121 640

Szegedi Tudomanyegyetem - Hungarian-Netherlands School of Educational Management

Hungary

EU Contribution

€ 170 960

KING'S COLLEGE LONDON

United Kingdom

EU Contribution

€ 494 360

QUEENSLAND UNIVERSITY OF TECHNOLOGY - QLD QUT

Australia

Project information

Grant agreement ID: 602633

Status

Closed project

  • Start date

    1 February 2014

  • End date

    31 January 2017

Funded under:

FP7-HEALTH

  • Overall budget:

    € 8 197 155

  • EU contribution

    € 5 996 726

Coordinated by:

ACADEMISCH ZIEKENHUIS LEIDEN

Netherlands